Q-omics provides the consensus-scored RPS27AP18 profile across patient tissues and cancer cell-line models. RPS27AP18 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RPS27AP18 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, RPS27AP18 RNA expression shows 6,602 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, BRCA, and STAD as cancer lineages where RPS27AP18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS27AP18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS27AP18 survival associations across molecular data types. RPS27AP18 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS27AP18 RNA expression–survival associations across cancer types. High RPS27AP18 expression shows unfavorable associations in MESO, KICH, ACC, KIRC, PAAD and LUSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .009). Together, the overview and detailed table identify MESO as the clearest survival context for RPS27AP18 RNA expression.
This table summarizes RPS27AP18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPS27AP18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS27AP18 shows higher tumor expression in BRCA, LUSC and LUAD. The BRCA box plot shows higher RPS27AP18 RNA expression in tumor versus normal tissue (log2 FC = +0.049, t-test p < 0.001).
This table shows molecular features associated with RPS27AP18 in patient tissues and cancer cell lines. In patient samples, RPS27AP18 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
